Evidence map›Paper›PMID 41036531›Full record

ArticleRespiratory medicine case reports2025

Cytokine release syndrome caused by dual immunotherapy with tremelimumab and durvalumab: A case report.

Takanori Ito, Saiki Yoshimura, Osamu Kanai, Naoki Fujimoto, Takuma Imakita, Issei Oi, Kohei Fujita, Kiminobu Tanizawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takanori ItoDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Saiki YoshimuraDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Osamu KanaiDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Naoki FujimotoDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Takuma ImakitaDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Issei OiDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Kohei FujitaDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.
Kiminobu TanizawaDivision of Respiratory Medicine, Center of Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa-Mukaihata, Fushimi-Ku, Kyoto, 612-8555, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and organ dysfunction. CRS is increasingly recognized as an immune-related adverse event caused by the use of immune checkpoint inhibitors (ICIs) to treat solid organ tumors. Herein, we report a life-threatening case of CRS that developed immediately after chemotherapy with tremelimumab and durvalumab in a patient with non-small-cell lung cancer. We administered high-dose corticosteroids and tocilizumab to the patient, which resulted in improvement. Regardless of the ICI class or immunoglobulin subclass, CRS should be considered when suspicious symptoms arise after ICI administration.

Indexed as

Cytokine release syndromeImmune checkpoint inhibitorsImmune-related adverse eventsImmunoglobulin G2POSEIDON regimenTremelimumab

Identifiers

PMID41036531
PMCPMC12481067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.